Skip to content

Prognostic value and immunotherapy analysis of immune cell related genes in laryngeal carcinoma

Prognostic value and immunotherapy analysis of immune cell related genes in laryngeal carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300067746
Enrollment
Unknown
Registered
2023-01-20
Start date
2023-01-31
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

laryngocarcinoma

Interventions

Sponsors

The First Hospital of Shanxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. The patients with laryngeal squamous cell carcinoma were initially diagnosed and did not receive radiotherapy, chemotherapy or biological therapy; 2. The patient has no hereditary family history, no other major diseases, no history of syphilis, tuberculosis, HIV, HPV, HBV and other infections; 3. Normal tissues adjacent to cancer should be confirmed without tumor cells by pathology; 4. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Have other tumors except laryngeal squamous cell carcinoma; 2. Fail to comply with the follow-up study of this project.

Design outcomes

Primary

MeasureTime frame
oxidized low den-sity lipoprotein receptor-1;Recombinant Renin Binding Protein ;

Countries

China

Contacts

Public ContactZhang Sen

The First Hospital of Shanxi Medical University

cccsl@163.com+86 139 9420 0909

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026